CVS Health (NYSE:CVS) Lowered to “Sell” Rating by StockNews.com

CVS Health (NYSE:CVS) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

A number of other research analysts have also recently issued reports on the stock. UBS Group boosted their price objective on shares of CVS Health from $60.00 to $62.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Cantor Fitzgerald restated a “neutral” rating and set a $62.00 price objective on shares of CVS Health in a report on Tuesday, October 1st. Wells Fargo & Company reduced their target price on shares of CVS Health from $61.00 to $60.00 and set an “equal weight” rating for the company in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft dropped their price target on CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. Finally, Evercore ISI increased their price objective on CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $73.00.

CVS Health Trading Up 1.5 %

Shares of NYSE CVS traded up $0.84 during midday trading on Thursday, hitting $55.11. The stock had a trading volume of 8,786,038 shares, compared to its average volume of 11,317,634. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. CVS Health has a fifty-two week low of $52.77 and a fifty-two week high of $83.25. The firm has a market cap of $69.35 billion, a P/E ratio of 13.99, a price-to-earnings-growth ratio of 0.94 and a beta of 0.55. The company’s 50-day simple moving average is $59.41 and its 200 day simple moving average is $58.79.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.08 by $0.01. The company had revenue of $95.43 billion during the quarter, compared to analysts’ expectations of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. CVS Health’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.21 EPS. Research analysts anticipate that CVS Health will post 5.44 EPS for the current year.

Institutional Investors Weigh In On CVS Health

A number of large investors have recently added to or reduced their stakes in CVS. MidAtlantic Capital Management Inc. bought a new position in shares of CVS Health in the third quarter valued at about $25,000. Livelsberger Financial Advisory acquired a new stake in CVS Health during the third quarter worth approximately $31,000. Crewe Advisors LLC bought a new stake in shares of CVS Health during the first quarter worth approximately $40,000. Reston Wealth Management LLC acquired a new position in shares of CVS Health in the third quarter valued at approximately $32,000. Finally, Kathleen S. Wright Associates Inc. bought a new position in shares of CVS Health during the third quarter worth approximately $33,000. Institutional investors own 80.66% of the company’s stock.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.